New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - fluorometholone 1 mg/ml;   - eye drops, solution - 0.1% w/v - active: fluorometholone 1 mg/ml   excipient: benzalkonium chloride dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 80 polyvinyl alcohol purified water sodium chloride sodium edetate sodium hydroxide

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - beractant - suspension for endotracheopulmonary instillation - 25mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - levobupivacaine hydrochloride - infusion - 1.25mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - levobupivacaine hydrochloride - infusion - .625mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - levobupivacaine hydrochloride - infusion - 1.25mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - levobupivacaine hydrochloride - infusion - .625mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - levodopa; carbidopa monohydrate - intestinal gel - 20mg/1ml ; 5mg/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - glecaprevir 100mg;  ; pibrentasvir 40mg;   - film coated tablet - active: glecaprevir 100mg   pibrentasvir 40mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium hypromellose iron oxide red lactose monohydrate macrogol 3350 propylene glycol monocaprylate sodium stearyl fumarate titanium dioxide tocofersolan - maviret is indicated for the treatment of adults and adolescents 12 years and older with chronic hepatitis c virus (hcv)

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 15.4mg equivalent to upadacitinib 15mg - modified release tablet - 15 mg - active: upadacitinib hemihydrate 15.4mg equivalent to upadacitinib 15mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry purple 85f100091 tartaric acid - rinvoq is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis. rinvoq may be used as monotherapy or in combination with methotrexate or other conventional synthetic disease modifying anti-rheumatic drugs (csdmards).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - risankizumab 90 mg/ml;   - solution for injection - 75 mg/0.83ml - active: risankizumab 90 mg/ml   excipient: polysorbate 20 sodium succinate sorbitol succinic acid water for injection - psoriasis: skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults.